H7N9 Bird Flu Might Easily Develop Resistance To Common Treatments, Research Shows

“Scientists have found that a mutation in a new strain of bird flu infecting people in China can render it resistant to a key first-line treatment drug without limiting its ability to spread in mammals,” Reuters reports. Researchers “found [H7N9] was highly resistant to Tamiflu, but also that it still had the ability to infect human cells in a laboratory dish, and spread between laboratory animals just as efficiently as its non-mutated counterpart,” the news agency writes, adding, “While this does not make H7N9 any more likely to develop into a human pandemic, researchers said it means doctors should be prudent in their use of antiviral medicines to treat H7N9 cases, and consider using drugs other than Tamiflu, such as GlaxoSmithKline’s Relenza, where possible” (Kelland, 12/10).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.